Parkinson's Disease (PD) Drugs market - 37% of Growth to Originate from Europe | Evolving Opportunities with AbbVie Inc. & Amneal Pharmaceuticals Inc. | Technavio

For more insights on the market share of various regions - Download a sample report in MINUTES

Read the 120-page report with TOC on "Parkinson's Disease (PD) Drugs Market Analysis Report by Drug class (DA and levodopa-carbidopa, MAO inhibitors, AChE inhibitors, glutamate inhibitors, and others) and Geography (Europe, North America, Asia, and ROW), and the Segment Forecasts,2020-2024". Gain competitive intelligence about market leaders. Track key industry opportunities, trends and threats. Information on marketing, brand, strategy and market development, sales, and supply functions. https://www.technavio.com/report/report/parkinsons-disease-drugs-market-industry-analysis

Parkinson's Disease (PD) Drugs Market: Vendor Analysis

The Parkinsons' disease (PD) drugs market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market. The Parkinson's disease (PD) drugs market report also offers information on several market vendors, including AbbVie Inc., Amneal Pharmaceuticals Inc., Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, Eisai Co. Ltd., GlaxoSmithKline Plc, Kyowa Kirin Co. Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., and UCB SA among others.

• AbbVie Inc. - It is a combination product containing carbidopa and levodopa for the treatment of PD.

To know about all major vendor offerings - Download a sample now!

Parkinson's Disease (PD) Drugs Market: Drivers & Challenges

The key factors driving growth in the Parkinson's disease (PD) drugs market is the drug launches. The array of new drug approvals and the launch of new drugs by key vendors are expected to drive the growth of the PD drugs market. In September 2020, Neurocrine Biosciences Inc. launched a new medication, a catechol-O-methyltransferase (COMT) inhibitor, for the treatment of PD. In January 2018, Adamas Pharmaceuticals Inc. announced the commercial launch of its flagship product, GOCOVRI (amantadine) extended-release capsules, for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. In June 2018, ACADIA Pharmaceuticals Inc. announced FDA approval of a new capsule dose formulation and a new tablet strength of NUPLAZID (pimavanserin) to help in the treatment of patients living with hallucinations and delusions associated with Parkinson's disease psychosis. Such regulatory approvals and commercial launches of drugs for PD are expected to drive the growth of the PD drugs market.

However, gene therapy to reverse the progression of PD is a Parkinson's disease (PD) drug market trend that is expected to have a positive impact in the coming years. PD is a long-lasting neurodegenerative disorder characterized by several features, such as cognitive impairment and a decrease in motor functions, which makes it an ideal target for gene therapy. Furthermore, the cause of the decrease in motor functions is well understood and can be effectively treated by gene transfer to damaged brain cells, using viral vectors technologies. The understanding of the genetic origin of PD has made considerable progress during the past few decades, and consequently, several novel strategies are now being investigated to deliver the neuroprotective gene to the basal ganglia nuclei of the brain, which may halt the progression of the disease. Lentivectors is an enveloped virus that belongs to the Retroviridae family. The ability to integrate into the host genome leading to stable transgene expression makes lentivectors a desirable vector for gene transfer. Adeno-associated virus (AAV)-based viral vector is the most widely used vector in carrying out clinical trials for PD and is derived from AAV. AAV presents a good safety profile, efficient transduction, and durable expression of neurons, thus, making it an ideal vector for gene transfer. Thus, the use of gene therapy technology for the development of PD drugs will boost the growth of the market during the forecast period.

To know about other drivers & challenges - Download a sample now!

Parkinsons Disease (PD) Drugs Market: Segmentation Analysis

Geography Outlook (Revenue, USD bn, 2019-2024)

• Europe - size and forecast 2019-2024
• North America - size and forecast 2019-2024
• Asia - size and forecast 2019-2024
• ROW - size and forecast 2019-2024

Drug Class Outlook(Revenue, USD bn, 2019-2024)

• DA and levodopa-carbidopa
• MAO inhibitors
• AChE inhibitors
• Glutamate inhibitors
•  Others

To know about the market contribution of each segment - Grab an exclusive Report

The competitive scenario provided in the Parkinsons' Disease (PD) Drugs Market report analyzes, evaluates, and positions companies based on various performance indicators. Some of the factors considered for this analysis include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, growth in market share, etc.Don't wait, Make a strategic approach & boost your business goals with our Parkinsons Disease (PD) Drugs Market Forecast Report - Buy Now!

Related Reports:

• The topical drugs market share is predicted to value at USD 70.95 billion by 2026, at an accelerating CAGR of 7.73%. Download a sample now!
• The marine pharmaceuticals market size is predicted to surge by USD 1.56 billion from 2021 to 2026 at a CAGR of 7.73%. Download a sample now!

Table of Content

Executive Summary

Market Landscape

• Market ecosystem
• Market characteristics
• Value chain analysis

Market Sizing

• Market definition
• Market segment analysis
• Market size 2019
• Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

• Five forces summary
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

Market Segmentation by Drug Class

• Market segments
• Comparison by drug class
• DA and levodopa-carbidopa - Market size and forecast 2019-2024
• MAO inhibitors - Market size and forecast 2019-2024
• AChE inhibitors - Market size and forecast 2019-2024
• Glutamate inhibitors - Market size and forecast 2019-2024
• Others - Market size and forecast 2019-2024
• Market opportunity by drug class

Customer landscape

• Overview

Geographic Landscape

• Geographic segmentation
• Geographic comparison
• Europe - Market size and forecast 2019-2024
• North America - Market size and forecast 2019-2024
• Asia - Market size and forecast 2019-2024
• ROW - Market size and forecast 2019-2024
• Key leading countries
• Market opportunity by geography
• Market drivers
• Market challenges
• Market trends

Vendor Landscape

• Competitive scenario
• Vendor landscape
• Landscape disruption

Vendor Analysis

• Vendors covered
• Market positioning of vendors
• AbbVie Inc.
• Amneal Pharmaceuticals Inc.
• Bausch Health Companies Inc.
• Boehringer Ingelheim International GmbH
• Eisai Co. Ltd.
• GlaxoSmithKline Plc
• Kyowa Kirin Co. Ltd.
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• UCB SA

Appendix

• Scope of the report
• Currency conversion rates for US$
• Research methodology
• List of abbreviations

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio